Recce Pharmaceuticals has cleared a critical regulatory hurdle in Indonesia with a successful inspection of its Phase 3 clinical trial site for diabetic foot infections, paving the way for potential approval in 2026 amid a large and growing market.
- Indonesian regulator completes inspection with no findings
- Phase 3 patient dosing continues at five sites
- Interim data expected after 155 patients enrolled
- Regulatory approval targeted for calendar year 2026
- Indonesia’s diabetes prevalence creates a US$1.5 billion market opportunity
Regulatory Inspection Clears Major Trial Site
Recce Pharmaceuticals (ASX:RCE) has secured a significant regulatory milestone with Indonesia’s National Agency of Drug and Food Control (Badan POM) completing a routine inspection of a Phase 3 clinical trial site without any findings that could impede progress. This validation of trial conduct, data integrity, and compliance with Good Clinical Practice standards underscores the robustness of Recce’s clinical operations in Indonesia.
The inspected trial, known as R327-G301, is testing Recce’s synthetic anti-infective candidate for diabetic foot infections, a complication affecting millions in Indonesia. The absence of regulatory concerns means patient dosing continues uninterrupted across five sites, with interim data analysis anticipated once 155 patients have completed treatment.
Strategic Importance of Indonesian Market
Indonesia’s diabetes prevalence, impacting over 20.9 million adults or roughly 11% of the population, positions it as a critical launchpad for Recce’s anti-infective portfolio. The company estimates the diabetic foot infection market opportunity in the Asia-Pacific region at approximately US$1.5 billion, making regulatory approval here a crucial commercial gateway.
This regulatory progress dovetails with Recce’s broader ambitions in the region, as highlighted in its recent update on advancing RECCE 327 with ASEAN registration targeted for 2026. That announcement detailed ongoing patient enrolment and strategic partnerships accelerating regional development, reinforcing the company’s pathway toward market entry across multiple Southeast Asian countries.
Clinical and Commercial Outlook
CEO James Graham emphasised that the inspection outcome bolsters confidence in the integrity of Recce’s data collection and the strength of its development pathway. With regulatory approval anticipated within the calendar year, Recce is poised to capitalise on a substantial unmet medical need in a market ranked fifth globally for diabetes prevalence.
Recce’s synthetic anti-infectives, including RECCE 327, are designed to tackle antibiotic-resistant superbugs, a growing global health threat. The company’s pipeline benefits from international recognition, including FDA Fast Track designation and inclusion on the World Health Organization’s priority pathogen list, underscoring the potential impact of its therapies.
Bottom Line?
While the regulatory inspection clears a key hurdle, Recce’s next critical moment will be the interim data readout, which will provide early signals on the drug’s efficacy and safety in a large patient cohort.
Questions in the middle?
- Will interim data from 155 patients confirm the trial’s promise and support regulatory approval?
- How rapidly can Recce leverage Indonesian approval to expand into other ASEAN markets?
- What competitive dynamics will Recce face in the Asia-Pacific diabetic foot infection treatment landscape?